774 related articles for article (PubMed ID: 9830799)
21. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
22. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
23. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
25. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
26. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A
Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970
[TBL] [Abstract][Full Text] [Related]
27. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
28. Experience with allogeneic and syngeneic blood stem cell transplantation in patients with hematological malignancies.
Rabitsch W; Reiter E; Keil F; Malzer R; Leitner G; Fischer G; Dieckman K; Kalhs P; Lechner K; Greinix HT
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S49-52. PubMed ID: 9916635
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
Min CK; Kim DW; Lee JW; Han CW; Min WS; Kim CC
Haematologica; 2001 Mar; 86(3):303-10. PubMed ID: 11255278
[TBL] [Abstract][Full Text] [Related]
30. [Nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study].
Liu L; Liu Q; Hao MW; Chen RA; Zhang JL; Wang LH; He H; Jiang SS; Liang YM
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1102-5. PubMed ID: 16029566
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
[TBL] [Abstract][Full Text] [Related]
33. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
[TBL] [Abstract][Full Text] [Related]
34. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
35. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
36. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
37. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
[TBL] [Abstract][Full Text] [Related]
38. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
39. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution.
Sanz GF; Saavedra S; Jiménez C; Senent L; Cervera J; Planelles D; Bolufer P; Larrea L; Martín G; Martínez J; Jarque I; Moscardó F; Plumé G; Andreu R; de la Rubia J; Barragán E; Solves P; Soler MA; Sanz MA
Bone Marrow Transplant; 2001 Apr; 27(7):693-701. PubMed ID: 11360108
[TBL] [Abstract][Full Text] [Related]
40. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]